[go: up one dir, main page]

CY1113164T1 - Στοματικως αποσαθρουμενη κονις περιλαμβανουσα κιλοσταζολη και μαννιτολη - Google Patents

Στοματικως αποσαθρουμενη κονις περιλαμβανουσα κιλοσταζολη και μαννιτολη

Info

Publication number
CY1113164T1
CY1113164T1 CY20121100910T CY121100910T CY1113164T1 CY 1113164 T1 CY1113164 T1 CY 1113164T1 CY 20121100910 T CY20121100910 T CY 20121100910T CY 121100910 T CY121100910 T CY 121100910T CY 1113164 T1 CY1113164 T1 CY 1113164T1
Authority
CY
Cyprus
Prior art keywords
mannitol
oral
kilostazol
dissulated
powders including
Prior art date
Application number
CY20121100910T
Other languages
English (en)
Inventor
Masafumi Toda
Tadashi Mukai
Original Assignee
Otsuka Pharmaceutical Company Limited.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Company Limited. filed Critical Otsuka Pharmaceutical Company Limited.
Publication of CY1113164T1 publication Critical patent/CY1113164T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει στοματικώς αποσαθρούμενη κόνιν περιλαμβάνουσα κιλοσταζόλη ως δραστικό συστατικό και μαννιτόλη σε ποσότητα 70% κατά βάρος ή και άνω, η οποία μπορεί να ληφθεί χωρίς ύδωρ και η οποία μπορεί να αποσαθρωθεί στη στοματική κοιλότητα. Η εν λόγω κόνις είναι κατάλληλη για ασθενείς στους οποίους χορηγείται κιλοσταζόλη, ειδικά για παρήλικες ασθενείς και ασθενείς πάσχοντες από δυσφαγία.
CY20121100910T 2005-06-29 2012-10-02 Στοματικως αποσαθρουμενη κονις περιλαμβανουσα κιλοσταζολη και μαννιτολη CY1113164T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005190156 2005-06-29
EP06780772A EP1901717B1 (en) 2005-06-29 2006-06-28 Orally disintegrating powder comprising cilostazol and mannitol

Publications (1)

Publication Number Publication Date
CY1113164T1 true CY1113164T1 (el) 2016-04-13

Family

ID=37120411

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100910T CY1113164T1 (el) 2005-06-29 2012-10-02 Στοματικως αποσαθρουμενη κονις περιλαμβανουσα κιλοσταζολη και μαννιτολη

Country Status (18)

Country Link
US (1) US20090110737A1 (el)
EP (1) EP1901717B1 (el)
JP (1) JP4131747B2 (el)
KR (1) KR101302293B1 (el)
CN (1) CN101212955B (el)
AR (1) AR057413A1 (el)
AU (1) AU2006263068B2 (el)
CA (1) CA2608629C (el)
CY (1) CY1113164T1 (el)
DK (1) DK1901717T3 (el)
ES (1) ES2388613T3 (el)
MY (1) MY147888A (el)
PL (1) PL1901717T3 (el)
PT (1) PT1901717E (el)
RU (1) RU2426529C2 (el)
SI (1) SI1901717T1 (el)
TW (1) TWI383809B (el)
WO (1) WO2007001086A1 (el)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2224914T3 (pl) 2007-09-14 2015-11-30 Wockhardt Ltd Kompozycje diacereiny
EP2262487A2 (en) * 2008-02-29 2010-12-22 Otsuka Pharmaceutical Co., Ltd. An orally disintegrating tablet of cilostazol
US20150141517A1 (en) * 2013-11-15 2015-05-21 Shin-Etsu Chemical Co., Ltd. Granulated composite, rapid release tablet and method for producing same
KR101748215B1 (ko) * 2015-05-29 2017-06-20 한국유나이티드제약 주식회사 경구용 서방성 제제
RU2694233C2 (ru) * 2017-10-13 2019-07-10 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Средство, обладающее ноотропным воздействием на организм

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029878A (en) * 1975-05-19 1977-06-14 Ici United States Inc. Process for preparing mannitol from glucose
ES2082723B1 (es) * 1994-07-20 1996-10-01 Lilly Sa Formulacion farmaceutica de fluoxetina en forma dispersable.
SE9803240D0 (sv) * 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
EG23951A (en) * 1999-03-25 2008-01-29 Otsuka Pharma Co Ltd Cilostazol preparation
US6740339B1 (en) * 1999-06-18 2004-05-25 Takeda Chemical Industries, Ltd. Quickly disintegrating solid preparations
EP1235561A2 (en) * 1999-11-30 2002-09-04 Panacea Biotec Limited Fast dissolving composition with prolonged sweet taste
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
JP2003238393A (ja) * 2002-02-15 2003-08-27 Otsuka Pharmaceut Co Ltd 施錠性が改善された錠剤及びその製造方法
US20050147666A1 (en) * 2002-03-06 2005-07-07 Kyowa Hakko Kogyo Co., Ltd. Tablets quickly disintegrating in oral cavity
ES2199061B1 (es) * 2002-06-10 2005-02-16 Laboratorios Vita, S.A. Comprimidos bucodispersables y procedimiento para su obtencion.
US8153161B2 (en) * 2003-12-09 2012-04-10 Dainippon Sumitomo Pharma Co., Ltd. Medicament-containing particle and a solid preparation containing the particle
JP2008536922A (ja) * 2005-04-22 2008-09-11 テバ・ファーマシューティカルズ・ユーエスエー・インコーポレイテッド オランザピンの医薬用経口崩壊錠

Also Published As

Publication number Publication date
PT1901717E (pt) 2012-08-07
HK1119063A1 (en) 2009-02-27
KR101302293B1 (ko) 2013-09-03
CA2608629C (en) 2013-11-19
SI1901717T1 (sl) 2012-10-30
JP4131747B2 (ja) 2008-08-13
RU2008103213A (ru) 2009-08-10
AU2006263068B2 (en) 2011-08-18
CN101212955B (zh) 2012-07-18
US20090110737A1 (en) 2009-04-30
RU2426529C2 (ru) 2011-08-20
WO2007001086A1 (en) 2007-01-04
CN101212955A (zh) 2008-07-02
DK1901717T3 (da) 2012-08-20
AU2006263068A1 (en) 2007-01-04
TW200740469A (en) 2007-11-01
JP2008528442A (ja) 2008-07-31
EP1901717A1 (en) 2008-03-26
PL1901717T3 (pl) 2012-12-31
AR057413A1 (es) 2007-12-05
ES2388613T3 (es) 2012-10-16
EP1901717B1 (en) 2012-07-18
MY147888A (en) 2013-01-31
KR20080021158A (ko) 2008-03-06
TWI383809B (zh) 2013-02-01
CA2608629A1 (en) 2007-01-04

Similar Documents

Publication Publication Date Title
CY1120994T1 (el) Καινοτομες συνθεσεις διαλυματος που περιεχουν κυτταρικο παραγοντα και χρηση αυτων για τη θεραπεια τραυματων
CY1114690T1 (el) Αντισωματα αντι-nrr notch1 και μεθοδοι χρησεις αυτων
CY1118179T1 (el) Φαρμακευτικη συνθεση
CY1110392T1 (el) Υποκατεστημενα παραγωγα μορφολινης και θειομορφολινης
CY1113963T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν ανταγωνιστες ακτιβινης-actriia και χρηση αυτων στην προληψη η' θεραπευτικη αγωγη πολλαπλου μυελωματος
NO20076687L (no) Oral doseringsform
CY1116895T1 (el) Τεμαχιο καθαρισμου τουαλετας
HUS1600021I1 (hu) MEK inhibitorok és módszerek azok felhasználására
CY1110026T1 (el) Ενωσεις πιπεραζινης βενζισοξαζολης και μεθοδοι χρησης εξ αυτων
ATE407998T1 (de) Reinigungsmittel
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
CY1111613T1 (el) Μεθοδοι για την αντιμετωπιση της μολυνσης απο hiv
CY1104993T1 (el) 4-(πιπεριδυλ- και πυρρολιδινυλ-αλκυλ-ουρεϊδο)-κινολινες ως ανταγωνιστες του υποδοχεα ουροτασινης ii
DE602005002562D1 (de) Pyrrolylsubstituierte pyridoä2,3-düpyrimidin-7-one und derivate davon als therapeutische mittel
CY1113164T1 (el) Στοματικως αποσαθρουμενη κονις περιλαμβανουσα κιλοσταζολη και μαννιτολη
HRP20090498T1 (hr) Kombinacija r,r-glikopirolata, roliprama i budesonida za liječenje upalnih oboljenja
EA200400357A1 (ru) Дезинтегрирующиеся в ротовой полости композиции валдекоксиба
EP1906968A4 (en) NEW SCHEMES FOR ORAL MONOPHASIC CONTRAZEPTIVA
CY1115384T1 (el) Αντι-φλεγμονωδης συνθεση
CO5660287A2 (es) Derivados de tetrahidrocarbazol y su uso farmaceutico
CL2008003231A1 (es) Compuestos derivados de 1,3-dihidro-5-isobenzofurancarbonitrilo sustituido, inhibidores selectivos de la recaptacion de serotonina; composicion farmaceutica; procedimiento de preparacion; utiles en el tratamiento y/o prevencion de la eyaculacion prematura.
MX2010003772A (es) Forma cristalina 1 de 2-(r)-2-metilpirrolidin-2-il-1h-benzimidazol -4-carboxamida.
SG171472A1 (en) Substituted aniline derivatives
CL2004001272A1 (es) Compuestos derivados de 3-(4-metoxi-7-morfolin-4-il-benzotiazol-2-il)-1,1-disustituido-urea; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento del compuesto en el tratamiento de enfermedades relacionadas co
ATE399532T1 (de) Medizinische seife